中山哪家医院治内痔最好中山怎样治疗大便出血,中山大便太大便血,中山便便有血怎么回事,中山肛肠手术的费用是多少,中山大便后便纸上有血,中山大便不干燥出血,中山华都肛肠医院PPH治疗方法怎么样

HAIFA, Israel, Oct. 5 (Xinhua) -- "It's a big day, a celebration shared by Israel, science and the entire world," Israeli researcher Daniel Shechtman, who won the 2011 Nobel Prize in chemistry, said here at a press conference at the Technion- Israel Institute of Technology.Shechtman, 70, has spent the past five decades at Technion. He is also an associate at the Ames Laboratory of the U.S. Department of Energy and has lectured at universities abroad."Thousands of scientists are currently researching the subject I developed and I'm sure that all of them view the prize as their accomplishment too," he told Xinhua, adding that, "Science (in general) wouldn't be here and be as prosperous and intricate as it is if not for the work of thousands of others around the world."The Swedish Royal Academy of Sciences on Wednesday announced Shechtman as the winner of this year's Nobel chemistry prize for his cutting-edge research on quasicrystals, a type of atom form that for decades was considered impossible by the global scientific community.The award panel explained that Shechtman's work, launched in early 1980s, has revolutionized the perception of solid matter.His work forced crstyallographers to revamp their basic conception that atoms inside crystals only have repeating and symmetrical patterns.Shechtman is the 10th Israeli scientist to win the Nobel Prize and the fourth to win the prize in chemistry.Ada Yonat, a researcher at the Weizmann Institute near Tel Aviv, received the chemistry prize in 2009.The announcement from Stockholm captured headlines in Israel, drawing praise from the country's leadership, who said Shechtman's achievement is a testament to the Jewish state's stature as a technological powerhouse.Israeli Prime Minister Benjamin Netanyahu said the winning of the Nobel Prize "expresses our people's intellect.""Every Israeli citizen is happy today and every Jew in the world is proud," a statement issued by Netanyahu's office quoted him as telling the scientist in a telephone call.Israeli President Shimon Peres, who is also a Nobel laureate, later called to congratulate Shechtman."You demonstrate that a thinking person who is hardworking and brave can make groundbreaking scientific discoveries," he said.

LOS ANGELES, Dec. 21 (Xinhua) -- The late Apple co-founder Steve Jobs will be honored posthumously with a Grammy award for his contributions to music technology, The Recording Academy announced on Wednesday.Jobs, who passed away Oct. 5 of pancreatic cancer, will receive a Trustees Award for helping create products "that transformed the way we consume music, TV, movies and books," the academy said in a prepared statement.The Apple Computer Inc. first received a Technical Grammy Award in 2002, for contributions of outstanding technical significance to the recording field, the academy said.Along with Jobs, bandleader and composer Dave Bartholomew, recording engineer Rudy Van Gelder will also receive the award.The academy also picked the Allman Brothers, Glen Campbell, Diana Ross and Brazilian pianist/singer/guitarist Antonio Carlos Jobim as recipients of Lifetime Achievement Awards. Jobim was known for composing "The Girl from Ipanema," a worldwide hit in the mid-1960s which won a Grammy for Record of the Year in 1965.Other artists, including trumpeter Wayne Jackson, saxophonist Andrew Love of the Memphis Horns,country legend George Jones,and the late Gil Scott-Heron were also named as recipients.German sound-technology firm Celemony and the late audio engineer Roger Nichols, who worked with artists including Ross, Placido Domingo, James Taylor and Stevie Wonder, were recognized with Grammy Technical Awards."This year's honorees offer a variety of brilliance, contributions and lasting impressions on our culture," said President/CEO of The Recording Academy Neil Portnow. "It is an honor to recognize such a diverse group of individuals whose talents and achievements have had an indelible impact on our industry."The honorees will be formally acknowledged during the 54th Annual Grammy Awards telecast at Staples Center in downtown Los Angeles on Feb. 12, 2012.

LOS ANGELES, Dec. 21 (Xinhua) -- The late Apple co-founder Steve Jobs will be honored posthumously with a Grammy award for his contributions to music technology, The Recording Academy announced on Wednesday.Jobs, who passed away Oct. 5 of pancreatic cancer, will receive a Trustees Award for helping create products "that transformed the way we consume music, TV, movies and books," the academy said in a prepared statement.The Apple Computer Inc. first received a Technical Grammy Award in 2002, for contributions of outstanding technical significance to the recording field, the academy said.Along with Jobs, bandleader and composer Dave Bartholomew, recording engineer Rudy Van Gelder will also receive the award.The academy also picked the Allman Brothers, Glen Campbell, Diana Ross and Brazilian pianist/singer/guitarist Antonio Carlos Jobim as recipients of Lifetime Achievement Awards. Jobim was known for composing "The Girl from Ipanema," a worldwide hit in the mid-1960s which won a Grammy for Record of the Year in 1965.Other artists, including trumpeter Wayne Jackson, saxophonist Andrew Love of the Memphis Horns,country legend George Jones,and the late Gil Scott-Heron were also named as recipients.German sound-technology firm Celemony and the late audio engineer Roger Nichols, who worked with artists including Ross, Placido Domingo, James Taylor and Stevie Wonder, were recognized with Grammy Technical Awards."This year's honorees offer a variety of brilliance, contributions and lasting impressions on our culture," said President/CEO of The Recording Academy Neil Portnow. "It is an honor to recognize such a diverse group of individuals whose talents and achievements have had an indelible impact on our industry."The honorees will be formally acknowledged during the 54th Annual Grammy Awards telecast at Staples Center in downtown Los Angeles on Feb. 12, 2012.

WASHINGTON, Oct. 18 (Xinhua) -- Heart failure (HF) hospitalizations dropped 29.5 percent nationally over the past decade, according to a study by Yale physicians to be published Wednesday in the Journal of the American Medical Association.The risk-adjusted rate of heart failure hospitalization fell from 2,845 to 2,007 per 100,000 person-years from 1998 to 2008 in a fee-for-service Medicare claims analysis by Dr. Jersey Chen of Yale University and colleagues.The team also found that the rate of hospitalization for black men dropped at a lower rate, and that one-year mortality rates declined slightly during that period, but remained high.HF imposes one of the highest disease burdens of any medical condition in the United States and the risk increases with age. As a result, HF ranks as the most frequent cause of hospitalization and re-hospitalization among senior Americans. HF is also one of the most resource-intensive conditions, with direct and indirect costs in the United States estimated at 39.2 billion U.S. dollars in 2010.The study showed that the HF hospitalization rates varied significantly from state to state. The decline in the hospitalization rate from 1998 to 2008 was significantly higher than the national average in 16 states and significantly lower in three states (Wyoming, Rhode Island and Connecticut).Chen and his team also found that risk-adjusted one-year mortality decreased from 31.7 percent to 29.6 percent between 1999 and 2008, a relative decline of 6.6 percent, with substantial variation in different states."Because of the substantial decline in HF hospitalizations, compared to the rate of 1998, there were an estimated 229,000 fewer HF hospitalizations in 2008," said Chen in a statement, adding that with a mean HF hospitalization cost of 18,000 dollars in 2008, this decline represents a savings of 4.1 billion dollars in fee-for-service Medicare."The overall decline in the heart failure hospitalization rate was mainly due to fewer individual patients being hospitalized with heart failure rather than a reduction in the frequency of repeat hospitalizations," said Chen.

WASHINGTON, Dec. 7 (Xinhua) -- Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study published Wednesday in the Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.Aging-related memory loss is associated with the gradual deterioration of the structure and function of synapses (the connections between brain cells) in brain regions critical to learning and memory, such as the hippocampus.Recent studies suggested that histone acetylation, a chemical process that controls whether genes are turned on, affects this process. Specifically, it affects brain cells' ability to alter the strength and structure of their connections for information storage, a process known as synaptic plasticity, which is a cellular signature of memory.In the current study, Cui-Wei Xie, of the University of California, Los Angeles, and colleagues found that compared with younger rats, hippocampi from older rats have less brain-derived neurotrophic factor (BDNF) -- a protein that promotes synaptic plasticity -- and less histone acetylation of the Bdnf gene. By treating the hippocampal tissue from older animals with a drug that increased histone acetylation, they were able to restore BDNF production and synaptic plasticity to levels found in younger animals."These findings shed light on why synapses become less efficient and more vulnerable to impairment during aging," said Xie, who led the study. "Such knowledge could help develop new drugs for cognitive aging and aging-related neurodegenerative diseases, such as Alzheimer's disease," she added.